Noofen®

Noofen®

Active substance: Phenibutum

Indications: asthenic and anxiously neurotic states; insomnia and night unrest in elderly patients; prevention of stress condition prior to operations; Meniere’s disease and vertigo, which is associated with dysfunction of vestibular analyser of various origins; prevention of kinetosis; stammering and ticks in children; auxiliary medication for the relief of alcohol abstinence syndrome.

Dose and quantity: 250 mg N20, 100 mg N15

Pharmaceutical form: tablets, powder for the preparation of a liquid for external use.

ATC Code: N06BX22

Nootropic agent

The active substance of Noofen® – phenibut can be considered to be a derivative of γ – aminobutyric acid (GABA), as well as β – phenylethylamine.  In addition to nootrophic action, Noofen® also has a tranquillising effect.

Uses:

In adults:

Doses and therapies are determined individually. See the summary of product characteristics for more detailed information.

Powder form must be used in children under 8 years of age.

In children from 8 to 14 years of age:

250 mg three times per day. The duration of the therapy course – 26 weeks.

In children from 3 to 7 years of age:

100 mg 2 – 3 times per day.

 

Advertising intended for specialists only.

Summary of Product Characteristics

The advertiser: AS Olainfarm, Olaine, Rūpnīcu iela 5, LV-2114. Material prepared: February 2020.

 CAREFULLY READ THE INSTRUCTIONS OR OTHER APPROPRIATE INFORMATION ON PACKAGING. CONSULT YOUR DOCTOR OR PHARMACIST ABOUT THE USE OF MEDICINES.

UNJUSTIFIED USE OF MEDICINES IS HARMFUL FOR HEALTH

Only health care professionals are allowed to read information about prescription drugs. Are you a health care professional?

Yes, I agree.

No